5F6I

Crystal Structure of Tier 2 Neutralizing Antibody DH428 from a Rhesus Macaque


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.32 Å
  • R-Value Free: 0.265 
  • R-Value Work: 0.218 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.

Bradley, T.Fera, D.Bhiman, J.Eslamizar, L.Lu, X.Anasti, K.Zhang, R.Sutherland, L.L.Scearce, R.M.Bowman, C.M.Stolarchuk, C.Lloyd, K.E.Parks, R.Eaton, A.Foulger, A.Nie, X.Karim, S.S.Barnett, S.Kelsoe, G.Kepler, T.B.Alam, S.M.Montefiori, D.C.Moody, M.A.Liao, H.X.Morris, L.Santra, S.Harrison, S.C.Haynes, B.F.

(2016) Cell Rep 14: 43-54

  • DOI: 10.1016/j.celrep.2015.12.017
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Antibodies that neutralize autologous transmitted/founder (TF) HIV occur in most HIV-infected individuals and can evolve to neutralization breadth. Autologous neutralizing antibodies (nAbs) against neutralization-resistant (Tier-2) viruses are rarely ...

    Antibodies that neutralize autologous transmitted/founder (TF) HIV occur in most HIV-infected individuals and can evolve to neutralization breadth. Autologous neutralizing antibodies (nAbs) against neutralization-resistant (Tier-2) viruses are rarely induced by vaccination. Whereas broadly neutralizing antibody (bnAb)-HIV-Envelope structures have been defined, the structures of autologous nAbs have not. Here, we show that immunization with TF mutant Envs gp140 oligomers induced high-titer, V5-dependent plasma neutralization for a Tier-2 autologous TF evolved mutant virus. Structural analysis of autologous nAb DH427 revealed binding to V5, demonstrating the source of narrow nAb specificity and explaining the failure to acquire breadth. Thus, oligomeric TF Envs can elicit autologous nAbs to Tier-2 HIVs, but induction of bnAbs will require targeting of precursors of B cell lineages that can mature to heterologous neutralization.


    Organizational Affiliation

    Duke Human Vaccine Institute, Departments of Medicine, Surgery and Immunology, Duke University School of Medicine, Durham, NCĀ 27710, USA. Electronic address: todd.bradley@duke.edu.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
DH428 Antibody Heavy Chain
B
227N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
DH428 Antibody Light Chain
C
216N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.32 Å
  • R-Value Free: 0.265 
  • R-Value Work: 0.218 
  • Space Group: P 21 2 21
Unit Cell:
Length (Å)Angle (°)
a = 73.106α = 90.00
b = 74.628β = 90.00
c = 102.620γ = 90.00
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
Cootmodel building
PHASERphasing
XSCALEdata scaling
PHENIXrefinement
XDSdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2016-01-13
    Type: Initial release
  • Version 1.1: 2016-01-20
    Type: Database references
  • Version 1.2: 2017-07-05
    Type: Source and taxonomy